Net Loss Per Share

12 Months Ended

Sep. 30, 2025

Earnings Per Share [Abstract]

Net Loss Per Share

NET LOSS PER SHARE

The following table presents the computation of basic and diluted net loss per share for the years ended September 30, 2025, 2024 and 2023.

	Year Ended September 30,
	2025		2024		2023
	(in thousands, except per share amounts)
Numerator:
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	$	(1,631)	$	(599,493)	$	(205,275)
Denominator:
Weighted-average basic shares outstanding (1)	133,758		119,784		106,750
Effect of dilutive securities	—		—		—
Weighted-average diluted shares outstanding (1)	133,758		119,784		106,750
Basic net loss per share	$	(0.01)	$	(5.00)	$	(1.92)
Diluted net loss per share	$	(0.01)	$	(5.00)	$	(1.92)

(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.

	Year Ended September 30,
	2025	2024	2023
	(in thousands)
Options	744	707	633
Restricted stock units	4,276	4,030	3,420
Total	5,020	4,737	4,053